Advances in herbal polysaccharides-based nano-drug delivery systems for cancer immunotherapy

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu H, Wang W, et al. Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. Expert Rev Anticancer Ther. 2021;21(1):107–119. doi:10.1080/14737140.2021.1837628.
   PubMed Web of Science ®Google Scholar
• Wang G, Lu X, Dey P, et al. Targeting Yap-dependent MDSC infiltration impairs tumour progression. Cancer Discov. 2016;6(1):80–95. doi:10.1158/2159-8290.CD-15-0224.
   PubMed Web of Science ®Google Scholar
• Moreno Ayala MA, Li Z, DuPage M. Treg programming and therapeutic reprogramming in cancer. Immunology. 2019;157(3):198–209. doi:10.1111/imm.13058.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Pan H, Li W, Chen Z, et al. Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumour. Bioact Mater. 2021;6(4):951–962. doi:10.1016/j.bioactmat.2020.09.025.
   PubMed Web of Science ®Google Scholar
• Akhter MH, Amin S. An investigative approach to treatment modalities for squamous cell carcinoma of skin. Curr Drug Deliv. 2017;14(5):597–612. doi:10.2174/1567201801666160906104254.
   PubMed Web of Science ®Google Scholar
• Ahmad, Javed, Ahmad, Mohammad Z, Akhter, Habban, et al. Surface-Engineered cancer nanomedicine: rational design and recent progress.Curr Pharm Des. 2020;26(11):1181–1190. doi:10.2174/1381612826666200214110645.
   PubMed Web of Science ®Google Scholar
• Habban Akhter M, Sateesh Madhav N, Ahmad J. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1188–1198. doi:10.1080/21691401.2018.1481863.
   PubMed Web of Science ®Google Scholar
• Nai J, Zhang C, Shao H, et al. Extraction, structure, pharmacological activities and drug carrier applications of angelica sinensis polysaccharide. Int J Biol Macromol. 2021;183:2337–2353. doi:10.1016/j.ijbiomac.2021.05.213.
   PubMed Web of Science ®Google Scholar
• Xue JX, Zhu ZY, Bian WH, et al. The traditional chinese medicine kangai injection as an adjuvant method in combination with chemotherapy for the treatment of breast cancer in chinese patients: a Meta-Analysis. Evid Based Complement Alternat Med. 2018;2018:6305645. doi:10.1155/2018/6305645.
   PubMed Web of Science ®Google Scholar
• Cao Y, Chen Z, Sun L, et al. Herb polysaccharide-based drug delivery system: fabrication, properties, and applications for immunotherapy. Pharmaceutics. 2022;14(8):1703. doi:10.3390/pharmaceutics14081703.
   PubMed Web of Science ®Google Scholar
• Yu Z, Shen X, Yu H, et al. Smart polymeric nanoparticles in cancer immunotherapy. Pharmaceutics. 2023;15(3):775. doi:10.3390/pharmaceutics15030775.
   PubMed Web of Science ®Google Scholar
• Yu L, Jin Y, Song M, et al. When natural compounds meet nanotechnology: nature-Inspired nanomedicines for cancer immunotherapy. Pharmaceutics. 2022;14(8):1589. doi:10.3390/pharmaceutics14081589.
   PubMed Web of Science ®Google Scholar
• Sun L, Zuo C, Liu X, et al. Combined photothermal therapy and lycium barbarum polysaccharide for topical administration to improve the efficacy of doxorubicin in the treatment of breast cancer. Pharmaceutics. 2022;14(12):2677. doi:10.3390/pharmaceutics14122677.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Xiang Y, Sheng R, et al. Polysaccharide-based nanomedicines for cancer immunotherapy: a review. Bioact Mater. 2021;6(10):3358–3382. doi:10.1016/j.bioactmat.2021.03.008.
   PubMed Web of Science ®Google Scholar
• Yu Y, Xie H, Zuo J, et al. Clinical research progress of first-line immunotherapy for extensive-stage small cell lung cancer. Precis Med Res. 2022;4(1):4. doi:10.53388/PMR20220004.
   Google Scholar
• Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793–801. doi:10.1016/s1074-7613(94)80021-9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang M, Wu HX, et al. Advancing to the era of cancer immunotherapy. Cancer Commun (Lond). 2021;41(9):803–829. doi:10.1002/cac2.12178.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;400(10358):1117–1129. doi:10.1016/S0140-6736(20)30417-7.
   Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–1369. doi:10.1038/70932.
   PubMed Web of Science ®Google Scholar
• Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370. doi:10.1016/j.molcel.2019.09.030.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34(1):539–573. doi:10.1146/annurev-immunol-032414-112049.
   PubMed Web of Science ®Google Scholar
• Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915–919. doi:10.1158/2159-8290.CD-15-0563.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. doi:10.3390/cancers12030738.
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022;185(3):576. doi:10.1016/j.cell.2022.01.008.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. doi:10.1016/S0140-6736(17)31601-X.
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM, Kirkwood JM, Marshall JL, et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6(1):35. doi:10.1186/s40425-018-0342-x.
   PubMedGoogle Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi:10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Wang H F, Wang S S, Huang M C, et al. Targeting immune-mediated dormancy: a promising treatment of cancer. Front Oncol. 2019;9(June):498. doi:10.3389/fonc.2019.00498.
   PubMedGoogle Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28. doi:10.1038/nm.4441.
   PubMed Web of Science ®Google Scholar
• Borrello I, Imus PH. BCMA CAR T cells: the winding path to success. J Clin Invest. 2019;129(6):2175–2177. doi:10.1172/JCI128372.
   PubMed Web of Science ®Google Scholar
• Chen F, Huang G. Preparation and immunological activity of polysaccharides and their derivatives. Int J Biol Macromol. 2018;112:211–216. doi:10.1016/j.ijbiomac.2018.01.169.
   PubMed Web of Science ®Google Scholar
• Abdolvahab MH, Darvishi B, Zarei M, et al. Interferons: role in cancer therapy. Immunotherapy. 2020;12(11):833–855. doi:10.2217/imt-2019-0217.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6-7):884–893. doi:10.1016/j.biochi.2007.04.006.
   PubMed Web of Science ®Google Scholar
• Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36(1):411–433. doi:10.1146/annurev-immunol-042617-053352.
   PubMed Web of Science ®Google Scholar
• Davar D, Ding F, Saul M, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the university of pittsburgh cancer institute. J Immunother Cancer. 2017;5(1):74. doi:10.1186/s40425-017-0279-5.
   PubMed Web of Science ®Google Scholar
• Amin A, White RL. Interleukin-2 in renal cell carcinoma: a has-been or a still-viable option? J Kidney Cancer VHL. 2014;1(7):74–83. doi:10.15586/jkcvhl.2014.18.
   PubMedGoogle Scholar
• Bonam SR, Partidos CD, Halmuthur SKM, et al. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38(9):771–793. doi:10.1016/j.tips.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJM, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10(5):475–480. doi:10.1038/nm1039.
   PubMed Web of Science ®Google Scholar
• Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991;252(5013):1662–1667. doi:10.1126/science.2047875.
   PubMed Web of Science ®Google Scholar
• Song H, Huang P, Niu J, et al. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma. Biomaterials. 2018;159:119–129. doi:10.1016/j.biomaterials.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Miao L, et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther. 2018;26(1):45–55. doi:10.1016/j.ymthe.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089–3094. doi:10.1200/JCO.2005.04.5252.
   PubMed Web of Science ®Google Scholar
• de Sostoa J, Dutoit V, Migliorini D. Oncolytic viruses as a platform for the treatment of malignant brain tumours. Int J Mol Sci. 2020;21(20):7449. doi:10.3390/ijms21207449.
   PubMed Web of Science ®Google Scholar
• Harrington K, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18(9):689–706. doi:10.1038/s41573-019-0029-0.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313–326. doi:10.1016/j.cell.2018.09.035.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–2116. doi:10.1200/JCO.1999.17.7.2105.
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. doi:10.1126/scitranslmed.3008002.
   PubMed Web of Science ®Google Scholar
• Hasan S, Awasthi P, Malik S, et al. Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19. Biotechnol Genet Eng Rev. 2022;Nov 21:1–40. doi:10.1080/02648725.2022.2147661.
   Web of Science ®Google Scholar
• Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. doi:10.1186/s13054-017-1678-1.
   PubMed Web of Science ®Google Scholar
• Akhter MH, Beg S, Tarique M, et al. Receptor-based targeting of engineered nanocarrier against solid tumors: recent progress and challenges ahead. Biochim Biophys Acta Gen Subj. 2020;1865(2):129777. doi:10.1016/j.bbagen.2020.129777.
   PubMed Web of Science ®Google Scholar
• Meng Y, Zhang Y, Jia N, et al. Synthesis and evaluation of a novel water-soluble high Se-enriched astragalus polysaccharide nanoparticles. Int J Biol Macromol. 2018;118(Pt B):1438–1448. doi:10.1016/j.ijbiomac.2018.06.153.
   PubMedGoogle Scholar
• Pang G, Zhang S, Zhou X, et al. Immunoactive polysaccharide functionalized gold nanocomposites promote dendritic cell stimulation and antitumour effects. Nanomedicine (Lond). 2019;14(10):1291–1306. doi:10.2217/nnm-2018-0390.
   PubMed Web of Science ®Google Scholar
• Pang G, Chen C, Liu Y, et al. Bioactive polysaccharide nanoparticles improve Radiation-Induced abscopal effect through manipulation of dendritic cells. ACS Appl Mater Interfaces. 2019;11[1] Pang(45):42661–42670. doi:10.1021/acsami.9b16814.
   PubMed Web of Science ®Google Scholar
• Xiong J, Jiang B, Luo Y, et al. Multifunctional nanoparticles encapsulating astragalus polysaccharide and gold nanorods in combination with focused ultrasound for the treatment of breast cancer. Int J Nanomedicine. 2020;15:4151–4169. doi:10.2147/IJN.S246447.
   PubMed Web of Science ®Google Scholar
• Guo C, Hou X, Liu Y, et al. Novel chinese angelica polysaccharide biomimetic nanomedicine to curcumin delivery for hepatocellular carcinoma treatment and immunomodulatory effect. Phytomedicine. 2021;80(September 2020):153356. doi:10.1016/j.phymed.2020.153356.
   PubMedGoogle Scholar
• Wang MZ, He X, Yu Z, et al. A nano drug delivery system based on angelica sinensis polysaccharide for combination of chemotherapy and immunotherapy. Molecules. 2020;25(13):3096. doi:10.3390/molecules25133096.
   Web of Science ®Google Scholar
• Zhang S, Pang G, Chen C, et al. Effective cancer immunotherapy by Ganoderma lucidum polysaccharide-gold nanocomposites through dendritic cell activation and memory T cell response. Carbohydr Polym. 2019;205:192–202. doi:10.1016/j.carbpol.2018.10.028.
   PubMed Web of Science ®Google Scholar
• Yu H, Yang Y, Jiang T, et al. Effective radiotherapy in tumour assisted by Ganoderma lucidum polysaccharide-Conjugated bismuth sulfide nanoparticles through radiosensitization and dendritic cell activation. ACS Appl Mater Interfaces. 2019;11(31):27536–27547. doi:10.1021/acsami.9b07804.
   PubMed Web of Science ®Google Scholar
• Liu K, Feng Z, Shan L, et al. Preparation, characterization, and antioxidative activity of bletilla striata polysaccharide/chitosan microspheres for oligomeric proanthocyanidins. Dry Technol. 2017;35(13):1629–1643. doi:10.1080/07373937.2016.1269123.
   Web of Science ®Google Scholar
• Mao Q, Min J, Zeng R, et al. Self-assembled traditional Chinese nanomedicine modulating tumour immunosuppressive microenvironment for colorectal cancer immunotherapy. Theranostics. 2022;12(14):6088–6105. doi:10.7150/thno.72509.
   PubMed Web of Science ®Google Scholar
• Xiong Y-X, Li N, Han M-M, et al. Rhodiola rosea polysaccharides-based nanoparticles loaded with DOX boosts chemo-immunotherapy for triple-negative breast cancer by re-educating tumour-associated macrophages. Int J Biol Macromol. 2023;239:124110. doi:10.1016/j.ijbiomac.2023.124110.
   PubMed Web of Science ®Google Scholar
• Joseph MM, Aravind SR, Varghese S, et al. PST-Gold nanoparticle as an effective anticancer agent with immunomodulatory properties. Colloids Surf B Biointerfaces. 2013;104:32–39. doi:10.1016/j.colsurfb.2012.11.046.
   PubMed Web of Science ®Google Scholar
• Tao S, Song Y, Ding S, et al. Dendrobium officinale polysaccharide-based carrier to enhance photodynamic immunotherapy. Carbohydr Polym. 2023;317(June):121089. doi:10.1016/j.carbpol.2023.121089.
   PubMedGoogle Scholar
• Guo H, Su Y, Guo C, et al. Polysaccharide based drug delivery systems for chinese medicines. Biocatal Agric Biotechnol. 2022;44:102441. doi:10.1016/j.bcab.2022.102441.
   Web of Science ®Google Scholar
• Liu X, Liu Q, Liang L, et al. The mechanism of astragalus membranaceus in treating peritoneal fibrosis by intervening the key syndrome and pathology based on Q-marker theory. Precis Med Res. 2022;4(2):10. doi:10.53388/PMR20220010.
   Google Scholar
• Ren Q, Zhao S, Ren C, et al. Astragalus polysaccharide alleviates LPS-induced inflammation injury by regulating miR-127 in H9c2 cardiomyoblasts. Int J Immunopathol Pharmacol. 2018;32:2058738418759180. doi:10.1177/2058738418759180.
   Web of Science ®Google Scholar
• Yin X, Chen L, Liu Y, et al. Enhancement of the innate immune response of bladder epithelial cells by astragalus polysaccharides through upregulation of TLR4 expression. Biochem Biophys Res Commun. 2010;397(2):232–238. doi:10.1016/j.bbrc.2010.05.090.
   PubMed Web of Science ®Google Scholar
• Lu Y, Xing QQ, Xu JY, et al. Astragalus polysaccharide modulates ER stress response in an OVA-LPS induced murine model of severe asthma. Int J Biol Macromol. 2016;93(Pt A):995–1006. doi:10.1016/j.ijbiomac.2016.09.058.
   PubMedGoogle Scholar
• Liu Z, Jiao Y, Wang Y, et al. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60(15):1650–1662. doi:10.1016/j.addr.2008.09.001.
   PubMed Web of Science ®Google Scholar
• Wersäll PJ, Blomgren H, Pisa P, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45(4):493–497. doi:10.1080/02841860600604611.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumour blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.009.
   PubMed Web of Science ®Google Scholar
• Qin T, Chen J, Wang D, et al. Optimization of selenylation conditions for chinese angelica polysaccharide based on immune-enhancing activity. Carbohydr Polym. 2013;92(1):645–650. doi:10.1016/j.carbpol.2012.08.097.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou T, Wang H, et al. Structural characterization and in vitro antitumour activity of an acidic polysaccharide from angelica sinensis (oliv.) diels. Carbohydr Polym. 2016;147:401–408. doi:10.1016/j.carbpol.2016.04.002.
   PubMed Web of Science ®Google Scholar
• Cao W, Li XQ, Wang X, et al. A novel polysaccharide, isolated from angelica sinensis (oliv.) diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway. Phytomedicine. 2010;17(8-9):598–605. doi:10.1016/j.phymed.2009.12.014.
   PubMed Web of Science ®Google Scholar
• Yang T, Jia M, Zhou S, et al. Antivirus and immune enhancement activities of sulfated polysaccharide from angelica sinensis. Int J Biol Macromol. 2012;50(3):768–772. doi:10.1016/j.ijbiomac.2011.11.027.
   PubMed Web of Science ®Google Scholar
• Chen D, Sun K, Mu H, et al. pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system. Int J Nanomedicine. 2012;7:2621–2630. doi:10.2147/IJN.S31757.
   PubMed Web of Science ®Google Scholar
• Chen H, Gu Z, An H, et al. Precise nanomedicine for intelligent therapy of cancer. Sci. China Chem. 2018;61(12):1503–1552. doi:10.1007/s11426-018-9397-5.
   Web of Science ®Google Scholar
• Cai J, Fu J, Li R, et al. A potential carrier for anti-tumour targeted delivery-hyaluronic acid nanoparticles. Carbohydr Polym. 2019;208:356–364. doi:10.1016/j.carbpol.2018.12.074.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Chen X, Xu X, et al. Tumor-Specific self-Degradable nanogels as potential carriers for systemic delivery of anticancer proteins. Adv Funct Materials. 2018;28(17):1707371. doi:10.1002/adfm.201707371.
   Web of Science ®Google Scholar
• Chen D, Lian S, Sun J, et al. Design of novel multifunctional targeting nano-carrier drug delivery system based on CD44 receptor and tumor microenvironment pH condition. Drug Deliv. 2016;23(3):808–813. doi:10.3109/10717544.2014.917130.
   PubMed Web of Science ®Google Scholar
• Yazdani HO, Huang H, Tsung A. Autophagy: dual response in the development of hepatocellular carcinoma. Cells. 2019;8(2):91. doi:10.3390/cells8020091.
   PubMed Web of Science ®Google Scholar
• Gonzalez PS, O’Prey J, Cardaci S, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563(7733):719–723. doi:10.1038/s41586-018-0729-3.
   PubMed Web of Science ®Google Scholar
• Lv X, Chen D, Yang L, et al. Comparative studies on the immunoregulatory effects of three polysaccharides using high content imaging system. Int J Biol Macromol. 2016;86:28–42. doi:10.1016/j.ijbiomac.2016.01.048.
   PubMed Web of Science ®Google Scholar
• Zhu N, Lv X, Wang Y, et al. Comparison of immunoregulatory effects of polysaccharides from three natural herbs and cellular uptake in dendritic cells. Int J Biol Macromol. 2016;93(Pt A):940–951. doi:10.1016/j.ijbiomac.2016.09.064.
   PubMedGoogle Scholar
• Kimmelman AC, White E. Autophagy and tumour metabolism. Cell Metab. 2017;25(5):1037–1043. doi:10.1016/j.cmet.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Tomoda M, Nakatsuka S, Tamai M, et al. Plant mucilages. VIII. Isolation and characterization of a mucous polysaccharide, "bletilla-glucomannan, "from bletilla striata tubers. Chem. Pharm. Bull. 1973;21(12):2667–2671. doi:10.1248/cpb.21.2667.
   Web of Science ®Google Scholar
• Peng Q, Li M, Xue F, et al. Structure and immunobiological activity of a new polysaccharide from bletilla striata. Carbohydr Polym. 2014;107:119–123. doi:10.1016/j.carbpol.2014.02.042.
   PubMed Web of Science ®Google Scholar
• Ding L, Shan X, Zhao X, et al. Spongy bilayer dressing composed of chitosan–Ag nanoparticles and chitosan–bletilla striata polysaccharide for wound healing applications. Carbohydr Polym. 2017;157:1538–1547. doi:10.1016/j.carbpol.2016.11.040.
   PubMed Web of Science ®Google Scholar
• Huang Y, Shi F, Wang L, et al. Preparation and evaluation of bletilla striata polysaccharide/carboxymethyl chitosan/carbomer 940 hydrogel for wound healing. Int J Biol Macromol. 2019;132:729–737. doi:10.1016/j.ijbiomac.2019.03.157.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Qi C, Wang H, et al. Biocompatible and degradable bletilla striata polysaccharide hemostasis sponges constructed from natural medicinal herb bletilla striata. Carbohydr Polym. 2019;226:115304. doi:10.1016/j.carbpol.2019.115304.
   PubMed Web of Science ®Google Scholar
• Ding M, Shao K, Wu L, et al. A NO/ROS/RNS cascaded-releasing nano-platform for gas/PDT/PTT/immunotherapy of tumours. Biomater Sci. 2021;9(17):5824–5840. doi:10.1039/d1bm00726b.
   PubMed Web of Science ®Google Scholar
• Zu YY, Liu QF, Tian SX, et al. Effective fraction of bletilla striata reduces the inflammatory cytokine production induced by water and organic extracts of airborne fine particulate matter (PM2.5) in vitro. BMC Complement Altern Med. 2019;19(1):369. doi:10.1186/s12906-019-2790-3.
   PubMed Web of Science ®Google Scholar
• Zhang C, Gao F, Gan S, et al. Chemical characterization and gastroprotective effect of an isolated polysaccharide fraction from bletilla striata against ethanol-induced acute gastric ulcer. Food Chem Toxicol. 2019;131:110539. doi:10.1016/j.fct.2019.05.047.
   PubMed Web of Science ®Google Scholar
• Wang Y, Han S, Li R, et al. Structural characterization and immunological activity of polysaccharides from the tuber of bletilla striata. Int J Biol Macromol. 2019;122:628–635. doi:10.1016/j.ijbiomac.2018.10.201.
   PubMed Web of Science ®Google Scholar
• Palao-Suay R, Gómez-Mascaraque LG, Aguilar MR, et al. Self-assembling polymer systems for advanced treatment of cancer and inflammation. Prog Polym Sci. 2016;53:207–248. doi:10.1016/j.progpolymsci.2015.07.005.
   Web of Science ®Google Scholar
• Xu Y, Jiang H, Sun C, et al. Antioxidant and hepatoprotective effects of purified rhodiola rosea polysaccharides. Int J Biol Macromol. 2018;117:167–178. doi:10.1016/j.ijbiomac.2018.05.168.
   PubMed Web of Science ®Google Scholar
• Deng S, Zhang G, Kuai J, et al. Lentinan inhibits tumour angiogenesis via interferon γ and in a T cell independent manner. J Exp Clin Cancer Res. 2018;37(1):260. doi:10.1186/s13046-018-0932-y.
   PubMedGoogle Scholar
• Cai Z, Li W, Wang H, et al. Antitumour effects of a purified polysaccharide from rhodiola rosea and its action mechanism. Carbohydr Polym. 2012;90(1):296–300. doi:10.1016/j.carbpol.2012.05.039.
   PubMed Web of Science ®Google Scholar
• Aravind SR, Joseph MM, Varghese S, et al. Antitumour and immunopotentiating activity of polysaccharide PST001 isolated from the seed kernel of tamarindus indica. ScientificWorldJournal. 2012;2012:361382. doi:10.1100/2012/361382.
   PubMedGoogle Scholar
• Khan MI, Hossain MI, Hossain MK, et al. Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review. ACS Appl Bio Mater. 2022;5(3):971–1012. doi:10.1021/acsabm.2c00002.
   PubMedGoogle Scholar
• Hossen S, Hossain MK, Basher MK, et al. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res. 2019;15:1–18. doi:10.1016/j.jare.2018.06.005.
   PubMed Web of Science ®Google Scholar